Beyond TNF-Inhibitors

Optimizing Care for Patients with IBD

Program Information

Release Date: November 27, 2018
Expiration Date: November 27, 2019

Target Audience

This enduring activity has been designed to meet the educational needs of gastroenterologists and gastroenterology fellows, nurse practitiioners, physician assistants, and all other healthcare professionals involved in the care and treatment of adult patients with IBD.

Educational Objectives

After completing this program, participants should be better able to:

Describe the mechanism, efficacy, and safety of new and emerging therapies in IBD

Incorporate practice guidelines/pathways and newer therapies effectively into clinical practice

Summarize clinical practice guidelines for health maintenance strategies, including immunization recommendations, for patients with IBD

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Gi Health Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accredited by

Provided by Gi Health Foundation

This event is neither sponsored by nor endorsed by ACG.
Supported by an educational grant from from Janssen Biotech, Inc. and Pfizer, Inc.

For more information, email us at, or call 1-877-782-4532.



Northwestern University
Feinberg School of Medicine
Chicago, IL


Cleveland Clinic
Cleveland, OH


University of California, San Diego
La Jolla, CA



Welcome and Introduction

Ulcerative Colitis:
From Pathways/Guidelines to the Clinic

Crohn’s Disease:
From Pathways/Guidelines to the Clinic

Optimizing Health Maintenance
Strategies in IBD

Panel Discussion and Q&A

Closing Remarks

Professor of Medicine
Medical Director, Digestive Health Center
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs

Dr. Hanauer is a board certified internist and gastroenterologist, and is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University's Feinberg School of Medicine. Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association's Inflammation, Immunology, and IBD Section. He is also a prior member of the Gastroenterology Specialty Board of the American Board of Internal Medicine and is a member and former-Chairman of the International Organization for Inflammatory Bowel Disease. Among his many honors, Dr. Hanauer received the ACG's Fiterman Foundation Joseph B. Kirsner Award in Gastroenterology and the Janssen Award for Clinical Excellence. He has served as a member of the U.S. FDA Gastrointestinal Drugs Advisory Committee since 1987, he Chaired the Committee from 1998-2000, and he presently serves the Center for Drug Development and Research as a Special Consultant defining new guidelines for clinical evaluation of IBD patients.

Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of many of the leading IBD therapies, including: Uceris®, Asacol HD®, Remicade®,Humira®, and Entyvio®.

Dr. Hanauer has authored over 425 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He is the former-Editor-in-Chief of Nature Clinical Practice Gastroenterology & Hepatology and currently serves as Associate Editor (IBD) of Clinical Gastroenterology and Hepatology. Dr. Hanauer is also a member of the editorial boards of other journals, most notably the American Journal of Gastroenterology and Inflammatory Bowel Diseases.

Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 1999, he was named the Joseph B. Kirsner Chair in Medicine and was designated Chief of the Section of Gastroenterology, Hepatology and Nutrition at the University of Chicago. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University's Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.


Consultant:  AbbVie, Actavis, Allergan, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Genentech, GSK, Hospita, Janssen, Lilly, Merck, Nestle, Novartis, Pfizer, Prometheus, Receptos, Salix, Samsung Bioepis, Sanofi-Avantis, Seres Health, Shire, Takeda, Therakos, Tigenex, UCB Pharma, and VHsquared,

Speaker's Bureau:  AbbVie, Janssen, and Takeda.

Clinical Research (Institution):  AbbVie, Allergan, Amgen, Celgene, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Sanofi-Avantis, Takeda, and UCB Pharma,

DSMB:  Bristol Myers Squibb

Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology
and Hepatology, Digestive Disease and Surgery Institute
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine, Lerner College of Medicine
Cleveland Clinic
Cleveland, Ohio

Miguel Regueiro earned his bachelor's degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School's Beth Israel Hospital.

Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.

Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Vice Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co-Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic. He also holds the Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology, Digestive Disease and Surgery Institute.

Dr. Regueiro's main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn's disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.


Grants/Research Support:  AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, and UCB.

Advisory Boards/Consultant:  AbbVie, Amgen, Janssen, Miraca Labs, Pfizer, UCB, and Takeda.

Professor of Medicine and Adjunct Professor of Surgery
Chief, Division of Gastroenterology
Vice Chair for Clinical Operations, Department of Medicine
Director, UCSD IBD Center
University of California San Diego and UC San Diego Health System

Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became a tenured Professor of Medicine and Adjunct Professor of Surgery at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. He is Vice Chair for Clinical Operations for the Department of Medicine, and a member of the Clinical Practice Operations Board (which oversees the clinical practice for the entire UC San Diego Health System). Dr. Sandborn has published over 695 peer reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. His h-index is 121. He is a member of the editorial board for the New England Journal of Medicine. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease.


Grants/Research Support:  AbbVie, Amgen, Atlantic Healthcare Limited, Celgene/Receptos, Genentech, Gilead Sciences, Janssen, Lily, and Takeda.

Consultant/Speaker's Bureau:  AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Conatus, Cosmo, Escalier Biosciences, Ferring, Genenentech, Gilead, Janssen, Lilly, Miraca Life Sciences, Nivalis Therapeutics, Novartis Nutrition Science Partners, Oppilan Pharma, Otsuka, Paul Hastings, Pfizer, Precision IBD, Progenity, Prometheus Laboratories, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust or HART), Salix Shire, Seres Therapeutics, Sigmoid Biotechnologies, Takeda, Tigenix, Tillotts Pharma, UCB Pharma, and Vivelix.

Stockholder:  Ritter Pharmaceuticals, Oppilan Pharma, Escalier Biosciences, Precision IBD, Progenity

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.